Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform

Nicholas O Fischer, Dina R. Weilhammer, Alexis Dunkle, Cynthia Thomas, Mona Hwang, Michele Corzett, Cheri Lychak, Wasima Mayer, Salustra Urbin, Nicole Collette, Jiun Chiun Chang, Gabriela G. Loots, Amy Rasley, Craig D. Blanchette

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 μg/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.

Original languageEnglish (US)
Article numbere93342
JournalPLoS One
Volume9
Issue number3
DOIs
StatePublished - Mar 27 2014
Externally publishedYes

Fingerprint

Cytotoxicity
Toxicity
Drug Stability
Nanosystems
Intranasal Administration
Molecules
Single-Stranded DNA
HDL Lipoproteins
Nanoparticles
Weight Loss
Therapeutics
therapeutics
Tissue
cytotoxicity
Lung
Fluids
Antibodies
immune response
toxicity
Chemical analysis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Fischer, N. O., Weilhammer, D. R., Dunkle, A., Thomas, C., Hwang, M., Corzett, M., ... Blanchette, C. D. (2014). Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform. PLoS One, 9(3), [e93342]. https://doi.org/10.1371/journal.pone.0093342

Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform. / Fischer, Nicholas O; Weilhammer, Dina R.; Dunkle, Alexis; Thomas, Cynthia; Hwang, Mona; Corzett, Michele; Lychak, Cheri; Mayer, Wasima; Urbin, Salustra; Collette, Nicole; Chang, Jiun Chiun; Loots, Gabriela G.; Rasley, Amy; Blanchette, Craig D.

In: PLoS One, Vol. 9, No. 3, e93342, 27.03.2014.

Research output: Contribution to journalArticle

Fischer, NO, Weilhammer, DR, Dunkle, A, Thomas, C, Hwang, M, Corzett, M, Lychak, C, Mayer, W, Urbin, S, Collette, N, Chang, JC, Loots, GG, Rasley, A & Blanchette, CD 2014, 'Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform', PLoS One, vol. 9, no. 3, e93342. https://doi.org/10.1371/journal.pone.0093342
Fischer, Nicholas O ; Weilhammer, Dina R. ; Dunkle, Alexis ; Thomas, Cynthia ; Hwang, Mona ; Corzett, Michele ; Lychak, Cheri ; Mayer, Wasima ; Urbin, Salustra ; Collette, Nicole ; Chang, Jiun Chiun ; Loots, Gabriela G. ; Rasley, Amy ; Blanchette, Craig D. / Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform. In: PLoS One. 2014 ; Vol. 9, No. 3.
@article{64e2e8e05078411bbaceb57ac9119250,
title = "Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform",
abstract = "Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 μg/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.",
author = "Fischer, {Nicholas O} and Weilhammer, {Dina R.} and Alexis Dunkle and Cynthia Thomas and Mona Hwang and Michele Corzett and Cheri Lychak and Wasima Mayer and Salustra Urbin and Nicole Collette and Chang, {Jiun Chiun} and Loots, {Gabriela G.} and Amy Rasley and Blanchette, {Craig D.}",
year = "2014",
month = "3",
day = "27",
doi = "10.1371/journal.pone.0093342",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform

AU - Fischer, Nicholas O

AU - Weilhammer, Dina R.

AU - Dunkle, Alexis

AU - Thomas, Cynthia

AU - Hwang, Mona

AU - Corzett, Michele

AU - Lychak, Cheri

AU - Mayer, Wasima

AU - Urbin, Salustra

AU - Collette, Nicole

AU - Chang, Jiun Chiun

AU - Loots, Gabriela G.

AU - Rasley, Amy

AU - Blanchette, Craig D.

PY - 2014/3/27

Y1 - 2014/3/27

N2 - Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 μg/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.

AB - Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 μg/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84899806300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899806300&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0093342

DO - 10.1371/journal.pone.0093342

M3 - Article

C2 - 24675794

AN - SCOPUS:84899806300

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e93342

ER -